- Poster presentation
- Open Access
PReS-FINAL-2054: Latent tuberculosis infection in patients with juvenile idiopathic arthritis undergoing methotrexate therapy: a longitudinal study with TST and ELISPOT
© Sztajnbok et al.; licensee BioMed Central Ltd. 2013
- Published: 5 December 2013
- Juvenile Idiopathic Arthritis
- Epidemiological Data
Latent tuberculosis infection (LTBI) has a higher risk of developing the active form in immunosuppressed patients. Controversy exists regarding the accuracy of the tuberculin skin test (TST) and methods based on the production of interferon gamma in the diagnosis of TB in pediatric and immunosuppressed patients.
To contribute to the knowledge about the diagnosis of LTBI and TB disease in patients with juvenile idiopathic arthritis (JIA) treated with methotrexate in a high burden country, evaluating the frequency and evolution before and after its initiation, agreement between TST and ELISPOT and sensitivity and specificity of ELISPOT.
This is an observational prospective longitudinal study where JIA patients starting methotrexate were evaluated in relation to clinical and epidemiological data, and TST and ELISPOT performed at inclusion and 3 and 12 months later.
There were a total of 24 patients. The prevalence of LTBI at inclusion was 20.8% (5/24 patients). The incidence of LTBI after initiation of immunosuppression was 26.3% (5/19 patients) and the prevalence of LTBI in the study as a whole was 41.6% (10/24 patients). The presence of epidemiological history positive for TB showed a relative risk of 2.0 for the development of LTBI. No patient developed TB disease. Only 2 patients had positive ELISPOT. Its sensitivity was 10%, specificity 92.8% and there was poor agreement between TST and ELISPOT.
We found a high frequency of LTBI in patients with JIA and no superiority of ELISPOT compared to TST in the diagnosis and monitoring. The decision to start treatment for LTBI in immunosuppressed children and adolescents in a high burden country should be based on the results of TST, as the cost of ELISPOT is much higher and the accuracy is not superior to TST.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.